E Bompas Selected Research

Sorafenib (BAY 43-9006)

10/2015	Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
12/2013	Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

E Bompas Research Topics

Disease

11	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 03/2009
5	Neoplasms (Cancer) 01/2019 - 10/2000
4	Leiomyosarcoma 01/2021 - 06/2010
3	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2019
2	Liposarcoma 01/2021 - 06/2012
2	Neutropenia 01/2021 - 09/2004
2	Solitary Fibrous Tumors 10/2015 - 12/2013
1	Tertiary Lymphoid Structures 01/2022
1	Leukopenia 01/2021
1	Giant Cell Tumor of Tendon Sheath 10/2019
1	Neurofibromatosis 1 (Neurofibromatosis Type I) 01/2019
1	Osteosarcoma (Osteogenic Sarcoma) 01/2019
1	Li-Fraumeni Syndrome 01/2019
1	Neurofibrosarcoma (MPNST) 03/2016
1	Chordoma 10/2015
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 09/2014
1	Chondrosarcoma 11/2013
1	Squamous Cell Carcinoma of Head and Neck 08/2012
1	Hemangiosarcoma (Angiosarcoma) 02/2012
1	Aggressive Fibromatosis (Desmoid) 01/2012
1	Synovial Sarcoma (Synovioma) 03/2009
1	Febrile Neutropenia 09/2004
1	Head and Neck Neoplasms (Head and Neck Cancer) 09/2004
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2004
1	Mucositis 09/2004

Drug/Important Bio-Agent (IBA)

6	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 06/2010
4	TrabectedinIBA 01/2021 - 10/2015
3	Ifosfamide FDA LinkGeneric 01/2022 - 06/2010
2	pembrolizumabIBA 01/2022 - 01/2019
2	Imatinib Mesylate (Gleevec)FDA Link 10/2019 - 09/2014
2	Sorafenib (BAY 43-9006)FDA Link 10/2015 - 12/2013
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Transaminases (Aminotransferases)IBA 01/2021
1	pazopanib FDA Link 01/2020
1	Gemcitabine FDA Link 01/2020
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2019
1	Tyrosine Kinase InhibitorsIBA 09/2014
1	masitinibIBA 09/2014
1	Investigational DrugsIBA 11/2013
1	Cisplatin (Platino)FDA LinkGeneric 04/2013
1	ErbB Receptors (EGF Receptor)IBA 08/2012
1	Insulin (Novolin)FDA Link 08/2012
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 08/2012
1	figitumumabIBA 08/2012
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2012
1	Dacarbazine (DIC)FDA LinkGeneric 06/2010
1	Methotrexate (Mexate)FDA LinkGeneric 09/2004
1	Docetaxel (Taxotere)FDA Link 09/2004
1	Coffee FDA Link 10/2000

Therapy/Procedure

12	Drug Therapy (Chemotherapy) 01/2022 - 10/2000
3	Therapeutics 01/2022 - 06/2012
2	Radiotherapy 01/2019 - 04/2013
2	Adjuvant Chemotherapy 04/2013 - 03/2009
2	Metastasectomy 02/2012 - 06/2010
1	Cytoreduction Surgical Procedures 01/2021
1	Immunotherapy 01/2019
1	Adjuvant Radiotherapy 03/2009